Published in J Atheroscler Thromb on February 03, 2010
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J (2010) 1.74
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol (2011) 1.09
Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J (2009) 1.07
PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest (2012) 1.00
Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation (2012) 0.94
Efficacy and safety of vorapaxar for the prevention of adverse cardiac events in patients with coronary artery disease: a meta-analysis. Cardiovasc Diagn Ther (2016) 0.89
Our expanding view of platelet functions and its clinical implications. J Cardiovasc Transl Res (2010) 0.88
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol (2012) 0.86
Emerging antiplatelet agents, differential pharmacology, and clinical utility. J Blood Med (2010) 0.83
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. Eur J Clin Pharmacol (2012) 0.81
Antiplatelet therapy: thrombin receptor antagonists. Br J Clin Pharmacol (2011) 0.78
Vorapaxar: targeting a novel antiplatelet pathway. P T (2011) 0.77
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol (2012) 0.77
Preventing platelet thrombosis with a PAR1 pepducin. Circulation (2012) 0.77
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med (2011) 0.76
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Ther Clin Risk Manag (2015) 0.75
PAR-1 inhibitor antiplatelet agents: performance below par? Indian Heart J (2012) 0.75
Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel) (2013) 0.75
Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Des Devel Ther (2015) 0.75
Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. Curr Cardiol Rev (2012) 0.75
Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci (2016) 0.75
Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med (2006) 7.62
Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature (2004) 7.21
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood (2004) 2.72
Defective vasculogenesis in systemic sclerosis. Lancet (2004) 2.38
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan). JACC Cardiovasc Interv (2010) 2.36
Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum (2006) 2.19
Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med (2002) 2.18
Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation (2011) 2.17
Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv (2011) 2.12
Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev (2008) 2.12
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum (2005) 2.11
Subclavian vein versus arm vein for totally implantable central venous port for patients with head and neck cancer: a retrospective comparative analysis. Cardiovasc Intervent Radiol (2010) 2.11
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09
Evaluation of pathogen detection from clinical samples by real-time polymerase chain reaction using a sepsis pathogen DNA detection kit. Crit Care (2010) 1.81
Efficacy of nasal bi-level positive airway pressure in congestive heart failure patients with cheyne-stokes respiration and central sleep apnea. Circ J (2005) 1.79
Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol (2003) 1.76
Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea. Am J Hypertens (2010) 1.72
Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care (2002) 1.70
Size-controlled stabilization of the superionic phase to room temperature in polymer-coated AgI nanoparticles. Nat Mater (2009) 1.70
Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol (2004) 1.62
Regulation of reactive oxygen species by Atm is essential for proper response to DNA double-strand breaks in lymphocytes. J Immunol (2007) 1.62
Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways. Am J Hematol (2005) 1.57
Catechin, a green tea component, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo. Haematologica (2005) 1.55
Impact of J-CTO score on procedural outcome and target lesion revascularisation after percutaneous coronary intervention for chronic total occlusion: a substudy of the J-CTO Registry (Multicentre CTO Registry in Japan). EuroIntervention (2016) 1.53
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res (2010) 1.53
Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery. Arterioscler Thromb Vasc Biol (2004) 1.48
Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia. Leuk Res (2006) 1.47
Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study. Cardiovasc Drugs Ther (2011) 1.46
The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica (2008) 1.46
Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv (2008) 1.45
Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress: implication of phosphorylation of p53 at Ser-15 residue by reactive oxygen species. Cancer Res (2004) 1.42
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J (2014) 1.42
Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br J Haematol (2003) 1.40
Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention. J Atheroscler Thromb (2014) 1.40
The impact of cutting balloon angioplasty for the treatment of diffuse in-stent restenosis. J Invasive Cardiol (2003) 1.39
Percutaneous bare Z-stent implantation as an alternative to surgery for acute aortic dissection with visceral ischemia. Catheter Cardiovasc Interv (2003) 1.39
Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation. Int J Hematol (2005) 1.39
A case of acute myocardial infarction treated with a new thrombectomy system. Catheter Cardiovasc Interv (2002) 1.39
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol (2002) 1.30
Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun (2004) 1.29
Function and role of microparticles in various clinical settings. Thromb Res (2008) 1.28
Presence and severity of Chlamydia pneumoniae and Cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes. Int Heart J (2006) 1.26
Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res (2005) 1.23
The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. Am J Hum Genet (2002) 1.23
The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J (2002) 1.22
Telomere length of normal leukocytes is affected by a functional polymorphism of hTERT. Biochem Biophys Res Commun (2006) 1.20
Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells (2006) 1.20
Mapping and ablation of idiopathic ventricular fibrillation from the Purkinje system. Heart Rhythm (2005) 1.20
In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther (2003) 1.18
Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. Chest (2008) 1.18
Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway. Cancer Sci (2007) 1.18
Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol (2005) 1.17
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther (2007) 1.15
Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun (2004) 1.12
Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail (2009) 1.12
Accurate structure factors and experimental charge densities from synchrotron X-ray powder diffraction data at SPring-8. Acta Crystallogr A (2006) 1.12
TNFalpha-induced ATF3 expression is bidirectionally regulated by the JNK and ERK pathways in vascular endothelial cells. Genes Cells (2004) 1.11
Rapid prototyping of temporal bone for surgical training and medical education. Acta Otolaryngol (2004) 1.11
Giant negative thermal expansion in the iron perovskite SrCu3Fe4O12. Angew Chem Int Ed Engl (2011) 1.11
Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol (2002) 1.09
Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation (2003) 1.09
Differences in the contribution of HLA-DR and -DQ haplotypes to susceptibility to adult- and childhood-onset type 1 diabetes in Japanese patients. Diabetes (2004) 1.08
Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res (2008) 1.08
Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun (2005) 1.07
Functional phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an impaired response to GP VI stimulation. Blood (2003) 1.07
Formulation study and drug release mechanism of a new theophylline sustained-release preparation. Int J Pharm (2005) 1.06
Control of charge transfer phase transition and ferromagnetism by photoisomerization of spiropyran for an organic-inorganic hybrid system, (SP)[Fe(II)Fe(III)(dto)3] (SP = spiropyran, dto = C2O2S2). J Am Chem Soc (2009) 1.06
Membrane-proximal {alpha}/{beta} stalk interactions differentially regulate integrin activation. J Biol Chem (2005) 1.06
[Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma]. Rinsho Ketsueki (2004) 1.06
Cardiomyogenic potential of mesenchymal progenitors derived from human circulating CD14+ monocytes. Stem Cells Dev (2005) 1.05
Increase of bone marrow-derived secretory lineage epithelial cells during regeneration in the human intestine. Gastroenterology (2005) 1.05
Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep (2012) 1.04
Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature. Int J Hematol (2004) 1.04
Angiographical severity of coronary atherosclerosis predicts death in the first year of hemodialysis. Int Urol Nephrol (2003) 1.04
Critical cysteine residues for regulation of integrin alphaIIbbeta3 are clustered in the epidermal growth factor domains of the beta3 subunit. Biochem J (2004) 1.03
Granulocyte colony stimulating factor-producing multiple myeloma associated with neutrophilia. Leuk Lymphoma (2004) 1.03
Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol (2008) 1.03
Transgenic up-regulation of alpha-CaMKII in forebrain leads to increased anxiety-like behaviors and aggression. Mol Brain (2009) 1.02
Ferroelectric columnar liquid crystal featuring confined polar groups within core-shell architecture. Science (2012) 1.02
NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood (2007) 1.02
Neurogenic potential of progenitors derived from human circulating CD14+ monocytes. Immunol Cell Biol (2006) 1.01
A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology (2003) 1.00
Coronary artery disease and a functional polymorphism of hTERT. Biochem Biophys Res Commun (2006) 1.00
Gelatinous degeneration in a recipient of allogeneic bone marrow transplantation. Int J Hematol (2006) 1.00
Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf. Blood (2012) 0.99
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study. J Atheroscler Thromb (2010) 0.99
Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood (2002) 0.99
Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest (2008) 0.99
Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant (2007) 0.99
Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells. Leuk Lymphoma (2002) 0.98